Overview

AZD5335 vs. Mirvetuximab Soravtansine in FR-high and AZD5335 vs. Chemotherapy in FR-low Platinum-resistant Ovarian Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2030-05-27

Target enrollment:

Participant gender:

Summary

The intention of the study is to demonstrate superiority of AZD5335 versus standard of care by assessment of progression-free survival (PFS) in women with high-grade, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, expressing high or low FR levels.

Phase:

PHASE3

Details

Lead Sponsor:

AstraZeneca

Collaborators:

European Network of Gynecological Oncological Trial Groups (ENGOT)
GOG Foundation, Inc. (GOG Foundation)
Ventana Medical Systems, Inc

Treatments:

liposomal doxorubicin
mirvetuximab soravtansine
Paclitaxel
Topotecan